Kolltan Pharmaceuticals
Biotechnology, New Haven, Connecticut, United States, 11-50 Employees
Phone Number: +15*********
Who is KOLLTAN PHARMACEUTICALS
Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agen...
Read More
-
Headquarters: New Haven, Connecticut, United States
-
Date Founded: 2007
-
Employees: 11-50
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
Michael Schmertzler
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from KOLLTAN PHARMACEUTICALS
Kolltan Pharmaceuticals Org Chart and Mapping
Carmela Senese
Executive Assistant to President and CEO, Svpchief Financial and Business Officer
Similar Companies to Kolltan Pharmaceuticals
Alphina Therapeutics
-
11-50
-
$ 25 Million to 50 Million
Arvinas
-
201-500
-
$ 100 Million to 250 Million
Biohaven
-
201-500
-
$ 250 Million to 500 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kolltan Pharmaceuticals
Answer: Kolltan Pharmaceuticals's headquarters are located at New Haven, Connecticut, United States
Answer: Kolltan Pharmaceuticals's phone number is +15*********
Answer: Kolltan Pharmaceuticals's official website is https://kolltan.com
Answer: Kolltan Pharmaceuticals's revenue is $50 Million to $100 Million
Answer: Kolltan Pharmaceuticals's SIC: 2834
Answer: Kolltan Pharmaceuticals's NAICS: 325412
Answer: Kolltan Pharmaceuticals has 11-50 employees
Answer: Kolltan Pharmaceuticals is in Biotechnology
Answer: Kolltan Pharmaceuticals top competitors include: Alphina Therapeutics , Arvinas , Biohaven
Answer: Kolltan Pharmaceuticals contact info: Phone number: +15********* Website: https://kolltan.com
Answer: Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month